Humayun Ashraf, MD
Pulmonary Disease · Hutchinson, KSNPI 1184980765
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (42.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Intuitive Surgical at 54.0% of the total. Reporting peaked in 2024 at $7,307 and has fallen 64.1% since, to $2,621 in 2025.
Across 266 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Veran Medical Technologies, Inc.$968
- Boehringer Ingelheim$896
- GSK$893
- AstraZeneca$689
- United Therapeutics Corporation$287
- plus $2K from 30 others
What the payments were for
- Travel & lodging$2,42018%
- Food & beverage$5,38440%
- Education$5,71042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $7,300 |
| Veran Medical Technologies, Inc. | 3 | $968 |
| Boehringer Ingelheim | 28 | $896 |
| GSK | 53 | $893 |
| AstraZeneca | 32 | $689 |
| United Therapeutics Corporation | 14 | $287 |
| Genentech USA, Inc. | 11 | $229 |
| Actelion Pharmaceuticals US, Inc. | 8 | $224 |
| Grifols USA, LLC | 9 | $214 |
| Mylan Specialty L.p. | 9 | $162 |
| Sunovion Pharmaceuticals Inc. | 15 | $154 |
| Inspire Medical Systems, Inc. | 7 | $121 |
| Regeneron Healthcare Solutions, Inc. | 6 | $114 |
| Amgen(2 entities) | 6 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Sanofi | 3 | $91 |
| Inari Medical, Inc. | 1 | $90 |
| Novartis | 5 | $88 |
| Harmony Biosciences LLC | 5 | $88 |
| Verona Pharma, Inc. | 5 | $88 |
| Philips North America LLC | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| ZOLL Respicardia, Inc. | 2 | $58 |
| Pfizer | 3 | $51 |
| Merck | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Sanofi US Services Inc. | 1 | $39 |
| Viatris Specialty LLC | 2 | $36 |
| Insmed, Inc. | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Electromed, Inc. | 2 | $21 |
| Hospira, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,269
- Spin$848
- TRELEGY ELLIPTA$125
How this compares
$13,515 in reported general payments places this provider in the 85th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 544 | $407,019 |
| OfevNintedanib Esylate | 21 | $204,948 |
| Dupixent PenDupilumab | 40 | $161,018 |
| Spiriva RespimatTiotropium Bromide | 173 | $115,605 |
| Breo ElliptaFluticasone/Vilanterol | 249 | $105,414 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $99,957 |
| NucalaMepolizumab | 13 | $45,533 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 338 | $41,963 |
| SymbicortBudesonide/Formoterol Fumarate | 139 | $41,600 |
| XolairOmalizumab | 23 | $38,233 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $36,805 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $27,624 |
| Incruse ElliptaUmeclidinium Bromide | 69 | $25,790 |
| YupelriRevefenacin | 12 | $18,152 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 504 | $15,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $893 | $618,714970 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $896 | $371,692286 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $689 | $141,557268 claims |
| Mylan Specialty L.p.Yupelri | $162 | $18,15212 claims |
| PfizerEliquis | $51 | $14,76916 claims |
| MerckBelsomra, Dulera | $45 | $7,98423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Hutchinson
- Robert SourkHutchinson$33K
- Moh'd Al-HalawaniHutchinson$15K
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Brandon BowersShawnee Mission$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.